CompanyGraph
Helps drug companies find patients for clinical trials using health records from over one billion people worldwide.
- Returns appear driven by leverage
- Depends onUpstream position: supplies 5 industries, depends on 0
- ScaleMarket cap is higher than 95% of all stocks globally
- FinancialsAltman Z-Score: grey zone
- Interpretations6 currently firing — 2 · 4
What this company is and how it runs — written from structure, not news.
IQVIA holds records covering more than one billion patients, assembled through years of individual regulatory negotiations with national health systems, hospital networks, and pharmacy chains in over 100 countries, and uses that dataset to locate eligible patients for clinical trials that smaller databases cannot statistically support. When those trials finish, their results flow back into the same dataset, making the next trial design more precise — so each completed study quietly strengthens the tool that wins the next contract. Drug companies that start a multi-year trial using IQVIA's patient records and methods lock themselves in for the life of that trial, because their regulatory submissions to the FDA and EMA name IQVIA's specific algorithms by reference, and switching providers mid-study would mean twelve to twenty-four months of revalidation work and the loss of the continuous patient history regulators depend on. The whole structure rests on data access that cannot be bought quickly — adding a single new country requires six to eighteen months of cross-border privacy negotiations under GDPR, HIPAA, or local law, which means that if a European enforcement ruling reclassifies currently anonymized records as requiring fresh patient consent, entire country feeds drop out and the statistical power that makes the loop worth entering in the first place shrinks with them.
How does this company make money?
IQVIA charges drug companies a fee for each patient enrolled through its clinical trial management services. It also sells subscriptions to its analytics software, charges consulting fees for real-world evidence studies, licenses its anonymized patient datasets to researchers, and collects milestone payments when a trial it supports reaches a regulatory submission.
What makes this company hard to replace?
A drug company that starts a multi-year clinical trial using IQVIA's patient records and data formats is locked in for the life of that trial. The regulatory submission references IQVIA's specific methods by name. Switching to a different provider mid-study would require twelve to twenty-four months of revalidation work and would break the continuous patient history that regulators rely on when reviewing the results. No drug company would risk a trial failure or delay of that magnitude.
What limits this company?
Adding a new country's health data requires a government-level privacy agreement under rules like GDPR in Europe or HIPAA in the United States. Those negotiations take six to eighteen months per country and cannot be sped up by spending more money. The calendar, not the budget, is the ceiling.
What does this company depend on?
IQVIA cannot operate without health record data flowing in from systems like Epic and Cerner; without privacy agreements with health authorities in the EU, US, and Asia-Pacific that allow it to hold and process that data; without networks of clinical investigators who actually recruit patients into trials; and without cloud computing infrastructure from Amazon Web Services and Microsoft Azure to store and analyze billions of records.
Who depends on this company?
Pharmaceutical companies running Phase III trials would face serious delays finding enough qualifying patients without IQVIA's identification tools. Health insurers like Anthem and Aetna use IQVIA's real-world evidence to decide which treatments they will cover. Smaller biotech companies working on rare diseases would have no realistic way to assemble a large enough global patient group to meet regulatory standards on their own.
How does this company scale?
Once IQVIA's analytics algorithms are built for one disease area, applying them to a new one costs relatively little. But every new country whose patient data IQVIA wants to add requires its own legal framework, its own privacy negotiation with local authorities, and its own clinical relationships — none of which can be automated. The software side grows easily; the data access side does not.
What external forces can significantly affect this company?
The biggest external threat is European GDPR enforcement — if rules around anonymized health data tighten, large portions of the platform could be shut off overnight. On the positive side, aging populations in wealthy countries mean more people living with chronic diseases, which expands the pool of patients available for studies. On the negative side, US-China trade restrictions are making it harder to include Chinese patient data in global trials, shrinking the reach of studies that need worldwide populations.
Where is this company structurally vulnerable?
If European regulators decide that the anonymized health records IQVIA currently uses actually require patients to give fresh, explicit permission, entire country-level data feeds would have to be switched off. Rare-disease and multi-country studies only work because the patient pool is enormous. Losing European records would shrink that pool below the size needed for the statistics to hold up — and that would undermine the core reason drug companies use the platform in the first place.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Near Multi-Tested High
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped advancing and pulled back, and (2) current price is back inside or just below that zone, near the top of its recent trading range. The retest is happening at a level the stock has reached before and turned away from.
Close In Upper Portion Of Recent Range, Bollinger Bands, And RSI
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
- Returns appear driven by leverage
4 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Elevated ROE With High Debt-to-Equity and Equity Multiplier
Three observations describe the configuration: return on equity is elevated, debt-to-equity is high (industry-benchmarked), and the equity multiplier (Assets / Equity) is large. The DuPont identity (ROE = ROA × Equity Multiplier) means leverage mechanically amplifies whatever ROA the company is producing; the observations do not separate the two contributions.
Cumulative Treasury Stock Significant With Elevated ROE And FCF-To-Equity
Three observations have aligned: the cumulative treasury-stock balance is significant relative to current equity, return on equity sits in the upper industry-benchmarked peer range, and free cash flow as a share of equity book value is in the upper portion of its mapped range.
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
Where is this company structurally exposed?
Elevated Leverage on Three Denominators
Three leverage observations have converged at elevated readings: debt is large relative to equity, large relative to total assets, and large relative to trailing operating cash flow. The capital structure is leveraged on three different denominators at once.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.